IDEXX Laboratories to Release 2014 First Quarter Financial Results
PR Newswire - Tue Apr 15, 1:30PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX), has scheduled the release of its 2014 first quarter financial results for Friday, April 25, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo
PR Newswire - Tue Apr 08, 1:17AM CDT
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Idexx Laboratories Larger Than S&P 500 Component LSI
TheOnlineInvestor.com - Mon Mar 31, 3:37PM CDT
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Idexx Laboratories, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example LSI Corp , according to The...
Recognitions, Board Elections, Acquisitions, and Organizational Changes - Analyst Notes on Omnicare, Cooper, Mednax, IDEXX, and Hologic
PR Newswire - Thu Mar 27, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Omnicare Inc. (NYSE: OCR), The Cooper Companies Inc. (NYSE: COO), MEDNAX, Inc. (NYSE: MD), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Hologic Inc. (NASDAQ: HOLX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Uptrend Call Working As Idexx Laboratories Stock Rises 16.3% (IDXX)
Comtex SmarTrend(R) - Wed Mar 19, 5:15PM CDT
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 3 months, Idexx Laboratories has returned 16.31% as of today's recent price of $123.74.
After Yesterday's Decline of 3.31%, Idexx Laboratories Offers Investors Better Value
Comtex SmarTrend(R) - Mon Mar 17, 6:10PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $123.64 to a high of $129.17. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $125.59 on volume of 627,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Idexx Laboratories (IDXX) Falls Further As It's Water-Logged And Getting Wetter
at The Street - Mon Mar 17, 12:23PM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Idexx Laboratories Shares Up 20.2% Since SmarTrend's Buy Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Mar 12, 11:07AM CDT
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 3 months, Idexx Laboratories has returned 20.18% as of today's recent price of $127.85.
IDEXX Laboratories names Daniel Junius as member of the board
M2 - Wed Mar 12, 7:59AM CDT
Diagnostics and information technology solutions for animal health care company IDEXX Laboratories (NASDAQ:IDXX) announced on Tuesday that Daniel M Junius has been elected as a member of the company's board of directors, with immediate effect.
IDEXX Laboratories Elects Daniel Junius to Board of Directors
PR Newswire - Tue Mar 11, 3:15PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced the unanimous election of Daniel M. Junius as a member of the Company's Board of Directors, effective March 11, 2014. Mr. Junius fills a vacancy on the Board for a Class I director, the remaining term for which ends at the Company's 2015 annual meeting of stockholders.
Idexx Laboratories Has Returned 18.4% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Mar 05, 9:46AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 2 months, Idexx Laboratories has returned 18.42% as of today's recent price of $125.98.
Idexx Laboratories Shares Up 18.4% Since SmarTrend's Buy Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Feb 26, 9:20AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 2 months, Idexx Laboratories has returned 18.44% as of today's recent price of $126.00.
IDEXX Laboratories to Present at Raymond James 35th Annual Institutional Investors Conference
PR Newswire - Tue Feb 25, 3:38PM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX), announced today that it will participate in the Raymond James 35th Annual Institutional Investors Conference. Brian McKeon, Executive Vice President and Chief Financial Officer, is scheduled to make a presentation on the Company on Tuesday, March 4, 2014 at 11:35 a.m. ET, at the JW Marriott Grande Lakes, Orlando, Florida. Individuals can access the live audio webcast of the presentation through a link on the home page of the IDEXX Laboratories website, www.idexx.com. An archived edition of the presentation will be available for 14 days via the same link.
Insider Trading Alert - IDXX, AGN And BGC Traded By Insiders
at The Street - Tue Feb 25, 9:02AM CST
Stocks with insider trader activity include IDXX, AGN and BGC
Shares of IDXX Up 18.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 18, 4:53PM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.38. In approximately 2 months, Idexx Laboratories has returned 18.06% as of today's recent price of $125.60.
This Company's "Dismal" Performance Masks Excellent Opportunity
John Leonard, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
Abaxis fell sharply after reporting disappointing results last month. However the recent recovery suggests the market is beginning to realize that the cause for the "dismal" results (the CEO's words) is most likely a one-off occurrence rather...
Navios Maritime Holdings to Ring the NYSE Closing Bell(R), Commemorating the Company's 60th Anniversary
Marketwire - Thu Feb 13, 7:32AM CST
Navios Maritime Holdings Inc. ("Navios Holdings"
Mark Luck Olson Joins Decision Resources Group As Executive Vice President, Global Services
PR Newswire - Wed Feb 12, 9:45AM CST
Decision Resources Group (DRG), one of the world's leading research and advisory firms focusing on healthcare insights, analysis and consulting, announced today that Mark Luck Olson has joined the Company as the Executive Vice President, Global Services. Mr. Olson was most recently an independent strategy consultant with 25 years of experience serving the healthcare industry. At DRG, he will be responsible for bringing together the various professional services brands within DRG (Abacus International, DRG Consulting, Millennium Research Group Consulting, PharmaStrat and Pinsonault Training) to create a cohesive services division that healthcare clients can benefit from holistically. Mr. Olson will report directly to Jim Lang, CEO, DRG.
Idexx Laboratories Up 12.8% Since SmarTrend Uptrend Call (IDXX)
Comtex SmarTrend(R) - Mon Feb 10, 10:03AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 2 month, Idexx Laboratories has returned 12.78% as of today's recent price of $119.98.
Aratana Therapeutics Announces Additions to Board of Directors
PR Newswire - Wed Feb 05, 3:10PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced additions to its Board of Directors. The Board has appointed two new members; Laura Brege, President and Chief Executive Officer of Nodality, Inc., a privately held life sciences company, and Merilee Raines, former Executive Vice President and Chief Financial Officer of companion animal health company IDEXX Laboratories. Mses. Brege and Raines will serve on the Audit Committee of the Board, with Ms. Brege as Chairperson. Aratana also announced the resignation of Board member Ronald Meeusen, Ph.D., Managing Partner of Cultivian Ventures, one of Aratana's early investors.